<DOC>
	<DOC>NCT00280865</DOC>
	<brief_summary>This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 2-week enrollment period, 4 week placebo single blind run in period followed by a 12-week double blind treatment period and a 3-week follow-up period</brief_summary>
	<brief_title>GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Provision of a written informed consent Men or women who are 30 to 80 years of age Female patients: postmenopausal or surgically sterile Diagnosed with type 2 diabetes with Cpeptide levels &gt; 0.8 ng/mL Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents Type 1 diabetes New York Heart Association heart failure Class III or IV Treatment with chronic insulin History of hypersensitivity or intolerance to any peroxisome proliferatoractivated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists. History of druginduced myopathy or druginduced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) Creatinine levels above 1.2 mg/dL Received any investigational product in other clinical studies within 30 days Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patientâ€™s safety or successful participation in the clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Tesaglitazar</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>